Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daglipzin for prevention of contrast-induced acute kidney injury after coronary angiography in patients with type 2 diabetes mellitus
ChiCTR2300076484Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in contrast-induced nephropathy (CIN), type 2 diabetes mellitus (T2DM) and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Beijing Hospital. Primary endpoints: CI-AKI within 48 hours after contrast (KDIGO criteria) and CI-AKI at 72 hours after contrast (ESUR criteria). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
contrast-induced nephropathy (CIN)type 2 diabetes mellitus (T2DM)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on ChiCTR2300076484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076484.